JP7282294B2 - アルテミシニン由来のトリマーおよびテトラマーおよびそれらの使用 - Google Patents

アルテミシニン由来のトリマーおよびテトラマーおよびそれらの使用 Download PDF

Info

Publication number
JP7282294B2
JP7282294B2 JP2020523749A JP2020523749A JP7282294B2 JP 7282294 B2 JP7282294 B2 JP 7282294B2 JP 2020523749 A JP2020523749 A JP 2020523749A JP 2020523749 A JP2020523749 A JP 2020523749A JP 7282294 B2 JP7282294 B2 JP 7282294B2
Authority
JP
Japan
Prior art keywords
compound
chr
pharmaceutically acceptable
alkyl
artesunate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504302A5 (enExample
JP2021504302A (ja
Inventor
ザオ，ミン
ジョウ，リ－ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2021504302A publication Critical patent/JP2021504302A/ja
Publication of JP2021504302A5 publication Critical patent/JP2021504302A5/ja
Application granted granted Critical
Publication of JP7282294B2 publication Critical patent/JP7282294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2020523749A 2017-11-21 2018-11-21 アルテミシニン由来のトリマーおよびテトラマーおよびそれらの使用 Active JP7282294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588921P 2017-11-21 2017-11-21
US62/588,921 2017-11-21
PCT/US2018/062356 WO2019104247A1 (en) 2017-11-21 2018-11-21 Artemisinin-derived trimers and tetramers and their use thereof

Publications (3)

Publication Number Publication Date
JP2021504302A JP2021504302A (ja) 2021-02-15
JP2021504302A5 JP2021504302A5 (enExample) 2022-01-04
JP7282294B2 true JP7282294B2 (ja) 2023-05-29

Family

ID=66632152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523749A Active JP7282294B2 (ja) 2017-11-21 2018-11-21 アルテミシニン由来のトリマーおよびテトラマーおよびそれらの使用

Country Status (5)

Country Link
US (2) US11358970B2 (enExample)
EP (1) EP3713566A4 (enExample)
JP (1) JP7282294B2 (enExample)
CN (2) CN111372583B (enExample)
WO (1) WO2019104247A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111372583B (zh) * 2017-11-21 2024-06-14 赵鸣 青蒿素衍生的三聚体和四聚体及其用途
CA3131244A1 (en) * 2019-02-26 2020-09-03 Mahmoud A. Eisohly Selected artemisinin dimers for the treatment of lashmaniasis
CN113264946A (zh) * 2021-05-11 2021-08-17 中国人民解放军陆军军医大学第一附属医院 一种双氢青蒿素衍生物及其在制备治疗、预防脑血管病药物中的应用
CN115282145A (zh) * 2022-09-05 2022-11-04 中南大学湘雅二医院 青蒿琥酯在制备治疗青光眼的药物或制剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074251A1 (en) 2003-01-23 2006-04-06 Man-Kil Jung Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411003A4 (en) 2009-03-24 2012-10-17 Univ Singapore USE OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHY (COPD)
DK2424880T3 (en) * 2009-04-28 2016-10-24 Res Dev Foundation Immunoreactive Ehrlichia p120 / p140 epitopes, and uses thereof
WO2010135427A2 (en) * 2009-05-19 2010-11-25 The Johns Hopkins University Trioxane monomers and dimers
WO2011071981A2 (en) 2009-12-08 2011-06-16 The Johns Hopkins University Anti-cytomegalovirus activity of artemisinin-derived dimers
CN102153564B (zh) 2011-01-31 2013-07-24 中国科学院上海药物研究所 含氮原子的青蒿素二聚体、其制备方法及用途
EP3269371A1 (en) 2011-06-10 2018-01-17 Queen Mary University of London Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease
CN103450468B (zh) * 2012-05-30 2016-06-15 北京凯正生物工程发展有限责任公司 青蒿琥酯聚乙二醇化衍生物、其药物组合物及其用途
WO2014090306A1 (en) 2012-12-12 2014-06-19 Queen Mary & Westfield College, University Of London Artemisinin and its derivatives for use in the treatment of kidney disease
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
CN105078964A (zh) 2015-08-20 2015-11-25 桂林医学院附属医院 青蒿琥酯在制备治疗特发性肺纤维化药物中的应用
CN111372583B (zh) * 2017-11-21 2024-06-14 赵鸣 青蒿素衍生的三聚体和四聚体及其用途
CN109467565B (zh) 2018-08-16 2020-07-10 云白药征武科技(上海)有限公司 双氢青蒿素三聚体及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074251A1 (en) 2003-01-23 2006-04-06 Man-Kil Jung Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Antiviral Res.，2018年，152，104-110
Bioorg. Med. Chem.，2001年，10，227-232
Bioorg. Med. Chem.，2009年，17，7949-7957
Eur. J. Med. Chem.，2017年，140，595-603

Also Published As

Publication number Publication date
CN111372583B (zh) 2024-06-14
WO2019104247A1 (en) 2019-05-31
EP3713566A1 (en) 2020-09-30
CN118546165A (zh) 2024-08-27
US20210079011A1 (en) 2021-03-18
EP3713566A4 (en) 2021-07-14
CN111372583A (zh) 2020-07-03
US12134624B2 (en) 2024-11-05
US20220275003A1 (en) 2022-09-01
JP2021504302A (ja) 2021-02-15
US11358970B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US12134624B2 (en) Artemisinin-derived trimers and tetramers and their use thereof
Raghuvanshi et al. Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: A mini-review
US7799776B2 (en) Indoleamine 2,3-dioxygenase (IDO) inhibitors
JP5057966B2 (ja) 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
US20110178050A1 (en) Use of cyclolignans for the treatment of a hyperactive immune system
JP2022031806A (ja) アルテスナート含有組成物
KR20250110848A (ko) Sting 작용제로서 헤테로사이클릭 화합물
CA3217111A1 (en) Use of medicament in treatment of tumor disease
JP5504891B2 (ja) 新規擬似糖脂質及びその用途
JPWO2002078685A1 (ja) 血管障害疾患用剤
AU1412299A (en) Nucleoside analog compositions and uses thereof
CN113024422A (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
EP3641756B1 (en) Tricyclic compounds as cyp1 inhibitors
EP1946758A1 (en) Treatment of acute myeloid leukemia
KR20080081310A (ko) 항암 효과가 높고 항말라리아 활성이 오래 지속되는트리옥산 이량체
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
KR20150014910A (ko) 허혈-재관류계 질환의 치료 화합물
CN108864114B (zh) 选择性a2a受体拮抗剂
CN101402640B (zh) 双酯化喜树碱衍生物及其制备方法和应用
RS58784B1 (sr) Farmaceutske kompozicije niske toksičnosti koje sadrže diterpenska jedinjenja sa antineoplastičnim dejstvom
JP7780235B2 (ja) 抗酸化化合物
CN101747300B (zh) 基于紫杉醇和氮芥的协同前药及其制备方法
US20070286906A1 (en) Dihydrobenzoquinone compounds
KR100466522B1 (ko) 항암활성을 갖는 ｊ 300 동충하초 추출물 및 이를함유하는 약제학적 조성물
CN113637031A (zh) 一种结构新颖的二价铂类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230417

R150 Certificate of patent or registration of utility model

Ref document number: 7282294

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150